Vildagliptin reduces plasma stromal cell‐derived factor‐1α in patients with type 2 diabetes compared with glimepiride

AIMS/INTRODUCTION: Dipeptidyl peptidase‐4 inhibitors might have pleiotropic protective effects on cardiovascular disease (CVD), in contrast to sulfonylureas. Therefore, we compared various CVD risk factors between vildagliptin and glimepiride. MATERIALS AND METHODS: We carried out a randomized, pros...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Diabetes Investig
Päätekijät: Park, Kyeong Seon, Kwak, SooHeon, Cho, Young Min, Park, Kyong Soo, Jang, Hak C, Kim, Seong Yeon, Jung, Hye Seung
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2016
Aiheet:
Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5334315/
https://ncbi.nlm.nih.gov/pubmed/27575011
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdi.12572
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia